Cenra Inc. (3716) reported revenue of NT$746.3 million for Oct 2026, +5.3% year on year and +10.6% from the previous month. Revenue for Jan–Oct 2026 was NT$6.95 billion (-2.4% year on year).
In Oct 2026, it ranked No. 10 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$746.3 million | +5.3% | +10.6% |
| Sep 2026 | NT$674.9 million | -11.0% | +6.8% |
| Aug 2026 | NT$631.8 million | -1.2% | -5.7% |
| Jul 2026 | NT$669.8 million | +3.5% | +0.9% |
| Jun 2026 | NT$663.8 million | -5.4% | +0.7% |
| May 2026 | NT$659.3 million | -4.4% | -2.4% |
| Apr 2026 | NT$675.7 million | -6.2% | -7.2% |
| Mar 2026 | NT$727.7 million | +0.1% | +17.1% |
| Feb 2026 | NT$621.6 million | -7.2% | -29.4% |
| Jan 2026 | NT$880.2 million | +2.8% | +14.3% |
| Dec 2025 | NT$770.3 million | -3.7% | +13.5% |
| Nov 2025 | NT$678.8 million | -6.5% | -4.3% |
| Oct 2025 | NT$709.1 million | -4.3% | -6.5% |
| Sep 2025 | NT$758.7 million | +1.3% | +18.7% |
| Aug 2025 | NT$639.4 million | — | -1.2% |
| Jul 2025 | NT$647 million | — | -7.8% |
| Jun 2025 | NT$701.6 million | — | +1.7% |
| May 2025 | NT$689.8 million | — | -4.3% |
| Apr 2025 | NT$720.6 million | — | -0.9% |
| Mar 2025 | NT$726.9 million | — | +8.6% |
| Feb 2025 | NT$669.5 million | — | -21.8% |
| Jan 2025 | NT$856.6 million | — | +7.0% |
| Dec 2024 | NT$800.3 million | — | +10.2% |
| Nov 2024 | NT$725.9 million | — | -2.1% |
| Oct 2024 | NT$741.2 million | — | -1.0% |
Jan–Oct 2026 cumulative: NT$6.95 billion (-2.4% YoY)
Other Biotech & Medical companies
Compare with peers: Cenra Inc. vs PEC / Cenra Inc. vs Lotus Pharm / Cenra Inc. vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16